Galkanezumab
Sammanfattning
Risk. "The active substance galcanezumab is a protein, the use of which will not alter the concentration or distribution of the substance in the environment. Therefore, galcanezumab is not expected to pose a risk to the environment."
Denna sammanfattande information kommer från utredningsrapport för Emgality (galkanezumab).
Detaljerad information
Utredningsrapport
Utredningsrapport för Emgality (galkanezumab) 20 september 2018 EMA/708631/2018.
"The active substance galcanezumab is a protein, the use of which will not alter the concentration or distribution of the substance in the environment. Therefore, galcanezumab is not expected to pose a risk to the environment."
Fass miljöinformation
Miljöinformation för galkanezumab saknas på fass.se (2020-10-06).
Författad vid avdelningen Kunskapsutveckling, Region Stockholm